Atia Vision Closes $10M In Series C Financing

Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular accommodating intraocular lens, announced today the closing of its second tranche of a Series C preferred stock financing, raising a total of $10M. Atia Vision’s unique technology enables natural accommodation, utilizing the ciliary muscles of the eye and providing for subsequent refractive correction, to restore the full range of functional vision for cataract patients. Led by The Capital Partnership (TCP), with participation from Medvance Incubator Partners and Cormorant Healthcare Fund, the financing officially closed on November 9, 2018. The funds raised in this round will support Atia Vision’s clinical efforts.